Doctors Note Logo

Published on: 9/13/2026

Can tadalafil cause dangerous heart or blood pressure problems in women?

Tadalafil can lower blood pressure in women, and while most healthy users experience only mild effects like flushing, headache, or dizziness, the drop can become dangerous when combined with nitrates, certain alpha-blockers, or other blood pressure medications. Women with unstable angina, recent heart attack or stroke, severe heart failure, uncontrolled hypertension, or very low baseline blood pressure face the highest risk of fainting, chest pain, or serious cardiovascular events. Rare but serious concerns include irregular heartbeat, sudden vision or hearing loss, and prolonged low blood pressure requiring emergency care. Because tadalafil is not FDA-approved for female sexual dysfunction, safety data in women remains limited, making individual risk factors especially important to review. There are several factors to consider, including drug interactions and warning signs to watch for, so see below to understand more.

If you are noticing dizziness, palpitations, chest discomfort, or unusual fatigue and are unsure whether a medication, your heart, or something else is behind it, guessing is the riskiest option. A free, instant, online symptom check takes just a few minutes, asks the same kinds of questions a clinician would, and helps you understand which possibilities fit your situation and how urgently you should act. It costs nothing, requires no appointment, and can help you walk into a pharmacy or doctor's office knowing exactly what to ask, which is far better than waiting to see if symptoms pass on their own.

Last reviewed for medical accuracy: 09/13/2026

answer background

Explanation

Can tadalafil cause dangerous heart or blood pressure problems in women?

Tadalafil (Cialis®) is a phosphodiesterase-5 (PDE5) inhibitor widely known for treating erectile dysfunction in men. In women, it’s used off-label for conditions like female sexual arousal disorder and approved for pulmonary arterial hypertension (PAH). Because tadalafil works by widening blood vessels and lowering blood pressure, it’s natural to wonder whether it might pose cardiovascular risks—especially in women. Below, we’ll review what the evidence tells us, outline possible issues, and offer practical advice.


1. How tadalafil works

Tadalafil blocks the PDE5 enzyme, which normally breaks down cyclic guanosine monophosphate (cGMP). Higher cGMP levels in blood vessel walls lead to relaxation of smooth muscle and increased blood flow. In pulmonary hypertension, this eases pressure in the lungs; in sexual arousal it may enhance genital blood flow.

Key effects on the cardiovascular system:

  • Vasodilation (widening of blood vessels)
  • Mild to moderate decrease in systemic blood pressure
  • Potential reflex changes in heart rate

2. Approved uses in women

  • Pulmonary arterial hypertension (PAH): FDA-approved dosing is 40 mg once daily. Clinical trials show improved exercise capacity and delayed disease progression.
  • Off-label sexual arousal: Some practitioners prescribe 5–20 mg when low genital blood flow is suspected, though robust randomized data are limited.

3. Blood pressure effects

Because tadalafil lowers vascular resistance, blood pressure (BP) can drop by 5–10 mmHg on average. In most healthy adults, this is well tolerated. However, certain situations can amplify the effect:

  • Concurrent nitrates: Medications like nitroglycerin (for chest pain) plus tadalafil can cause severe, life-threatening hypotension.
  • Alpha-blockers: Used for urinary symptoms or high blood pressure; combined use may lead to dizziness or fainting.
  • Existing low BP: Baseline hypotension (< 90/50 mmHg) raises risk of symptomatic drops.

Women with any of these factors need careful evaluation before using tadalafil.


4. Heart rhythm and other risks

Though uncommon, tadalafil may trigger or unmask cardiac issues:

  • Reflex tachycardia: A drop in BP can provoke a compensatory increase in heart rate. In women with arrhythmias, this may worsen palpitations.
  • Chest pain or angina: If you have coronary artery disease, sudden vasodilation might shift blood flow and precipitate pain.
  • Rare serious events: Post-marketing reports mention heart attack, stroke, and life-threatening arrhythmias. Causality is hard to prove; most cases involve other risk factors (smoking, high cholesterol, poorly controlled hypertension).

5. Who’s at higher risk?

Tadalafil is generally safe for women without cardiovascular disease, but extra caution is needed if you have:

  • Known coronary artery disease, angina, history of heart attack or stroke
  • Uncontrolled hypertension (> 170/100 mmHg) or severe hypotension (< 90/50 mmHg)
  • Use of nitrates or nitric oxide donors in any form
  • Significant arrhythmias, cardiomyopathy, or heart failure
  • Severe liver or kidney impairment (affects drug clearance)

6. Recognizing warning signs

Stop tadalafil and seek medical help if you experience:

  • Sudden, severe dizziness or fainting
  • Chest pain, pressure, or heaviness
  • Rapid or irregular heartbeat
  • Severe headache, vision changes or sudden nausea
  • Unexplained shortness of breath

These symptoms may indicate dangerously low blood pressure, heart ischemia, or an arrhythmia.


7. What the studies say in women

Clinical trials in PAH patients (including women) show tadalafil is generally well tolerated:

  • Improved 6-minute walk distance by 25–35 meters
  • Low incidence of cardiovascular adverse events in controlled settings
  • Most common side effects: headache, flushing, dyspepsia—usually mild

Data on sexual function in women are less robust, but adverse event profiles mirror those in male studies.


8. Safe use recommendations

Before starting tadalafil, discuss these points with your doctor:

  • Complete cardiovascular evaluation if you have risk factors
  • Share a full medication list—especially nitrates, α-blockers, antihypertensives
  • Begin with the lowest effective dose:
    • PAH: 40 mg daily
    • Off-label sexual use: often 5–10 mg as needed
  • Monitor your BP and heart rate at home, particularly during the first week
  • Avoid grapefruit juice (can raise tadalafil levels)

9. Lifestyle and monitoring

In addition to medication, maintaining heart health is key:

  • Eat a balanced diet rich in fruits, vegetables, whole grains
  • Keep sodium intake moderate to support stable blood pressure
  • Exercise as tolerated—walking, swimming, or cycling
  • Limit alcohol (can potentiate BP-lowering and dizziness)
  • Schedule regular follow-up visits and lab tests as recommended

10. When to get help

Never ignore symptoms that could signal serious issues. If you’re unsure whether your symptoms are medication-related or life-threatening, consider a free, online symptom check, using the doctor approved Ubie Symptom Checker. If you have chest pain, prolonged fainting, sudden vision changes or persistent palpitations, call emergency services immediately.


11. Key takeaways

  • Tadalafil’s blood-pressure-lowering effects can rarely become dangerous, especially with nitrates or in pre-existing heart disease.
  • Women with uncontrolled hypertension, hypotension, arrhythmias, or on certain drugs need extra caution.
  • Serious cardiovascular events are unusual but reported—recognize warning signs.
  • Always discuss your full medical history and current medications with a healthcare provider.
  • Consider monitoring BP and heart rate when starting or adjusting the dose.

Speak to your doctor before starting or changing tadalafil. Only they can determine your personal risk and ensure safe use. If you experience any concerning symptoms—or simply want guidance—schedule an appointment promptly. Your health and safety come first.

(References)

  • * Khera M, Goldstein I. Erectile dysfunction. BMJ Clin Evid. 2011 Jun 29;2011. Epub 2011 Jun 29. PMID: 21711956; PMCID: PMC3217797.

  • * Galiè N, Barberà JA, Frost AE, Ghofrani HA, Hoeper MM, McLaughlin VV, Peacock AJ, Simonneau G, Vachiery JL, Grünig E, Oudiz RJ, Vonk-Noordegraaf A, White RJ, Blair C, Gillies H, Miller KL, Harris JH, Langley J, Rubin LJ, AMBITION Investigators. Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension. N Engl J Med. 2015 Aug 27;373(9):834-44. doi: 10.1056/NEJMoa1413687. PMID: 26308684.

  • * Yamamura A, Fujitomi E, Ohara N, Tsukamoto K, Sato M, Yamamura H. Tadalafil induces antiproliferation, apoptosis, and phosphodiesterase type 5 downregulation in idiopathic pulmonary arterial hypertension in vitro. Eur J Pharmacol. 2017 Sep 5;810:44-50. doi: 10.1016/j.ejphar.2017.06.010. Epub 2017 Jun 8. PMID: 28603047.

  • * Ruopp NF, Cockrill BA. Diagnosis and Treatment of Pulmonary Arterial Hypertension: A Review. JAMA. 2022 Apr 12;327(14):1379-1391. doi: 10.1001/jama.2022.4402. PMID: 35412560.

  • * Grünig E, Jansa P, Fan F, Hauser JA, Pannaux M, Morganti A, Rofael H, Chin KM. Randomized Trial of Macitentan/Tadalafil Single-Tablet Combination Therapy for Pulmonary Arterial Hypertension. J Am Coll Cardiol. 2024 Jan 30;83(4):473-484. doi: 10.1016/j.jacc.2023.10.045. PMID: 38267108.

  • * Hoeper MM, Oerke B, Wissmüller M, Leuchte H, Opitz C, Halank M, Seyfarth HJ, Baldus S, Bauersachs J, Böhm M, Ghofrani HA, Konstantinides S, Olsson KM, Wachter R, Lam CSP, Aminossadati B, Rosenkranz S. Tadalafil for Treatment of Combined Postcapillary and Precapillary Pulmonary Hypertension in Patients With Heart Failure and Preserved Ejection Fraction: A Randomized Controlled Phase 3 Study. Circulation. 2024 Aug 20;150(8):600-610. doi: 10.1161/CIRCULATIONAHA.124.069340. Epub 2024 Jun 28. PMID: 38939948.

  • * McLaughlin VV, Sitbon O, Chin KM, Galiè N, Hoeper MM, Kiely DG, MacDonald G, Martin N, Mathai SC, Peacock A, Tawakol A, Torbicki A, Vonk Noordegraaf A, Rosenkranz S. Initial combination therapy with macitentan and tadalafil in patients with pulmonary arterial hypertension, with and without cardiac comorbidities. Eur J Heart Fail. 2024 Nov;26(11):2379-2391. doi: 10.1002/ejhf.3319. Epub 2024 Jul 5. PMID: 38966990; PMCID: PMC11659495.

  • * Jehle DVK, Sunesra R, Uddin H, Paul KK, Joglar AA, Michler OD, Blackwell TA, Gaalema D, Hayek S, Jneid H. Benefits of Tadalafil and Sildenafil on Mortality, Cardiovascular Disease, and Dementia. Am J Med. 2025 Mar;138(3):441-448.e3. doi: 10.1016/j.amjmed.2024.10.039. Epub 2024 Nov 10. PMID: 39532245.

  • * Ölmestig J, Mortensen KN, Thomas MB, Fagerlund B, Naveed N, Nordling MM, Nielsen MKK, Rasmussen BS, Christensen H, Iversen HK, Poulsen MB, Siebner HR, Kruuse C. Tadalafil Treatment in Patients With Cerebral Small Vessel Disease: The ETLAS-2 Randomized Clinical Trial. Stroke. 2025 Oct;56(10):2846-2857. doi: 10.1161/STROKEAHA.125.051602. Epub 2025 Jul 28. PMID: 40718899; PMCID: PMC12447817.

  • * Li Z, Liu A, Qian A, Feng W, Yang J, Tian X, Zhao Z, Zhou S, Zhao AZ, Mu Y, Li F. Tadalafil protects against renal fibrosis after ischemia-reperfusion injury by inhibiting Akt/NF-κB signaling pathway. Eur J Pharmacol. 2025 Dec 15;1009:178388. doi: 10.1016/j.ejphar.2025.178388. Epub 2025 Nov 19. PMID: 41271150.

Thinking about asking ChatGPT?Ask me instead

Tell your friends about us.

We would love to help them too.

smily Shiba-inu looking

For First Time Users

What is Ubie’s Doctor’s Note?

We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.

Was this page helpful?

Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.